Display options
Cite
Waluś-Miarka M, Kapusta M, Miarka P, et al. Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes. Cardiovasc Ther. 2021;2021:7956161doi: 10.1155/2021/7956161.
Waluś-Miarka, M., Kapusta, M., Miarka, P., Kawalec, E., & Idzior-Waluś, B. (2021). Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes. Cardiovascular therapeutics, 20217956161. https://doi.org/10.1155/2021/7956161
Waluś-Miarka, Małgorzata, et al. "Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes." Cardiovascular therapeutics vol. 2021 (2021): 7956161. doi: https://doi.org/10.1155/2021/7956161
Waluś-Miarka M, Kapusta M, Miarka P, Kawalec E, Idzior-Waluś B. Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes. Cardiovasc Ther. 2021 Dec 21;2021:7956161. doi: 10.1155/2021/7956161. eCollection 2021. PMID: 35024053; PMCID: PMC8714359.
Copy Download .nbib Format: NLM
Share it on

Cardiovasc Ther. 2021 Dec 21;2021:7956161. doi: 10.1155/2021/7956161. eCollection 2021.

Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes.

Cardiovascular therapeutics

Małgorzata Waluś-Miarka, Maria Kapusta, Przemysław Miarka, Ewa Kawalec, Barbara Idzior-Waluś

Affiliations

  1. Department of Metabolic Diseases, Jagiellonian University Medical College, Jakubowskiego 2, 30-688 Krakow, Poland.
  2. University Hospital, Krakow, Poland.
  3. Department of Biochemistry, Jagiellonian University, Medical College, Poland.
  4. Department of Nephrology, Jagiellonian University Medical College, Poland.

PMID: 35024053 PMCID: PMC8714359 DOI: 10.1155/2021/7956161

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in the regulation of LDL metabolism. There is evidence that circulating PCSK9 is a cardiovascular risk factor. In this study, we determined factors associated with circulating PCSK9 in a group of patients with type 2 diabetes mellitus (DM2). Material included 116 consecutive patients with DM2 from outpatient diabetes clinic. Circulating PCSK9, PTX3, apolipoprotein (apo) B100, apo B48, and apo C3 levels were determined by ELISA, apo A1 by immunoturbidimetry. The mean (sd) age of patients was 59.1 (11.1) years, the mean (sd) values of serum PCSK9 were 255.4 (106.97) ng/ml. Circulating PCSK9 correlated negatively with age (

Copyright © 2021 Małgorzata Waluś-Miarka et al.

Conflict of interest statement

All authors declare no conflict of interest.

References

  1. Atherosclerosis. 2016 May;248:117-22 - PubMed
  2. J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8 - PubMed
  3. Coron Artery Dis. 2019 Nov;30(7):528-535 - PubMed
  4. Curr Pharm Des. 2018;24(31):3654-3657 - PubMed
  5. Eur Heart J. 2019 Jan 21;40(4):357-368 - PubMed
  6. Clin Sci (Lond). 2015 Mar;128(6):379-85 - PubMed
  7. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3486-3495 - PubMed
  8. Cardiovasc Res. 2020 Apr 1;116(5):908-915 - PubMed
  9. Endocr Rev. 2021 Oct 09;: - PubMed
  10. Theranostics. 2020 May 30;10(16):7100-7110 - PubMed
  11. Clin Chem. 2007 Oct;53(10):1814-9 - PubMed
  12. Biochim Biophys Acta Mol Cell Biol Lipids. 2021 Aug;1866(8):158968 - PubMed
  13. Ann Med. 2016 Aug;48(5):384-91 - PubMed
  14. Cardiovasc Res. 2018 Jul 1;114(8):1145-1153 - PubMed
  15. Eur J Prev Cardiol. 2017 Jul;24(10):1095-1101 - PubMed
  16. J Clin Endocrinol Metab. 2009 Jul;94(7):2537-43 - PubMed
  17. J Lipid Res. 2018 Feb;59(2):207-223 - PubMed
  18. Nutr Metab Cardiovasc Dis. 2017 Apr;27(4):342-349 - PubMed
  19. Hepatology. 2008 Aug;48(2):646-54 - PubMed
  20. Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1454-9 - PubMed
  21. Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):237-245 - PubMed
  22. Diabetes Obes Metab. 2021 Nov 2;: - PubMed
  23. J Clin Lipidol. 2018 Jan - Feb;12(1):130-136 - PubMed
  24. J Clin Lipidol. 2018 Jan - Feb;12(1):211-218 - PubMed
  25. J Am Coll Cardiol. 2017 Feb 21;69(7):789-800 - PubMed
  26. JHEP Rep. 2019 Nov 05;1(6):418-429 - PubMed
  27. Front Immunol. 2019 Apr 17;10:823 - PubMed
  28. Sci Transl Med. 2014 Oct 15;6(258):258ra143 - PubMed
  29. Curr Opin Endocrinol Diabetes Obes. 2015 Apr;22(2):119-25 - PubMed
  30. Atherosclerosis. 2017 Jul;262:113-122 - PubMed
  31. Clin Chem. 2009 Sep;55(9):1637-45 - PubMed
  32. Nat Immunol. 2020 Jan;21(1):30-41 - PubMed
  33. J Clin Invest. 2021 Jan 19;131(2): - PubMed
  34. Atherosclerosis. 2018 Nov;278:82-90 - PubMed
  35. Biochem Biophys Res Commun. 2008 Sep 19;374(2):341-4 - PubMed
  36. Clin Biochem. 2020 Mar;77:20-25 - PubMed
  37. Lancet Gastroenterol Hepatol. 2021 Nov;6(11):903-913 - PubMed
  38. Biochem Biophys Res Commun. 2007 Sep 21;361(2):451-6 - PubMed
  39. Cardiovasc Diabetol. 2019 Oct 31;18(1):144 - PubMed
  40. J Cell Physiol. 2019 Mar;234(3):2345-2355 - PubMed
  41. Pol Arch Intern Med. 2019 Aug 29;129(7-8):499-505 - PubMed
  42. Curr Cardiol Rev. 2017;13(4):274-282 - PubMed
  43. Biomedicines. 2021 Jul 19;9(7): - PubMed
  44. BMC Gastroenterol. 2006 Nov 02;6:33 - PubMed
  45. Eur Heart J. 2016 Feb 7;37(6):554-60 - PubMed
  46. Am J Pathol. 2021 Aug;191(8):1385-1397 - PubMed
  47. Diabetes Care. 2018 Oct;41(10):2212-2219 - PubMed
  48. Clin Chem. 2008 Jun;54(6):1038-45 - PubMed

Publication Types